Claudin-4, mitogen-activated protein kinase kinase 4, and stratifin are markers of gastric adenocarcinoma precursor lesions

Cancer Epidemiology Biomarkers and Prevention

Volumn 15, Issue 2, 2006, Pages 281-287

  Cunningham, Steven C ^a,c   Kamangar, Farin ^b   Kim, Min P ^a,g   Hammoud, Sommer ^a   Haque, Raqeeb ^a   Iacobuzio Donahue, Christine A ^a   Maitra, Anirban ^a   Ashfaq, Raheela ^a   Hustinx, Steven ^d   Heitmiller, Richard E ^a,e   Choti, Michael A ^a   Lillemoe, Keith D ^a,f   Cameron, John L ^a   Yeo, Charles J ^a   Schulick, Richard D ^a   Montgomery, Elizabeth ^a,h  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

^e UNION MEMORIAL HOSPITAL   (United States)

^f INDIANA UNIVERSITY   (United States)

^g BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^h JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CALVASCULIN; CLAUDIN 4; DNA TOPOISOMERASE (ATP HYDROLYSING); EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FASCIN; MESOTHELIN; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; PROTEIN 14 3 3; STRATIFIN; TOPOISOMERASE IIALPHA; UNCLASSIFIED DRUG;

AGED; ANTIBODY LABELING; ARTICLE; CLAUDIN 4 GENE; CONTROLLED STUDY; DIAGNOSTIC VALUE; EPIDERMAL GROWTH FACTOR RECEPTOR GENE; FASCIN GENE; FEMALE; GASTROINTESTINAL DYSPLASIA; GENE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; INTESTINE METAPLASIA; MALE; MESOTHELIN GENE; MKK4 GENE; NON INVASIVE MEASUREMENT; ONCOGENE NEU; PRECANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; S110A4 GENE; SENSITIVITY AND SPECIFICITY; STOMACH ADENOCARCINOMA; STOMACH EPITHELIUM; STRATIFIN GENE; TISSUE MICROARRAY; TOPOISOMERASE IIALPHA GENE;

ADENOCARCINOMA; AGED; EXONUCLEASES; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MAP KINASE KINASE 4; MEMBRANE PROTEINS; METAPLASIA; MICROARRAY ANALYSIS; NEOPLASM PROTEINS; PRECANCEROUS CONDITIONS; STOMACH NEOPLASMS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 33644770016     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-05-0539     Document Type: Article

References (54)

1. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin 2004;54:8-29.
2. Morson BC. Gastric polyps composed of intestinal epithelium. Br J Cancer 1955;9:550-7.
3. Morson BC. Carcinoma arising from areas of intestinal metaplasia in the gastric mucosa. Br J Cancer 1955;9:377-85.
4. Morson BC. Intestinal metaplasia of the gastric mucosa. Br J Cancer 1955;9:365-76.
5. Correa P. Human gastric carcinogenesis: a multistep and multifactorial process-First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res 1992;52:6735-40.
6. Boussioutas A, Li H, Liu J, et al. Distinctive patterns of gene expression in premalignant gastric mucosa and gastric cancer. Cancer Res 2003;63:2569-77.
7. SAGEmap. Serial analysis of gene expression. National Center for Biotechnology Information, 2004. Accessed 2004 March 2.
8. Iacobuzio-Donahue CA, Maitra A, Shen-Ong GL, et al. Discovery of novel tumor markers of pancreatic cancer using global gene expression technology. Am J Pathol 2002;160:1239-49.
9. Ryu B, Jones J, Blades NJ, et al. Relationships and differentially expressed genes among pancreatic cancers examined by large-scale serial analysis of gene expression. Cancer Res 2002;62:819-26.
10. Nacht M, Ferguson AT, Zhang W, et al. Combining serial analysis of gene expression and array technologies to identify genes differentially expressed in breast cancer. Cancer Res 1999;59:5464-70.
11. Hough CD, Sherman-Baust CA, Pizer ES, et al. Large-scale serial analysis of gene expression reveals genes differentially expressed in ovarian cancer. Cancer Res 2000;60:6281-7.
12. Rangel LB, Agarwal R, D'Souza T, et al. Tight junction proteins claudin-3 and claudin-4 are frequently overexpressed in ovarian cancer but not in ovarian cystadenomas. Clin Cancer Res 2003;9:2567-75.
13. Ji J, Chen X, Leung SY, et al. Comprehensive analysis of the gene expression profiles in human gastric cancer cell lines. Oncogene 2002;21:6549-56.
14. Nichols LS, Ashfaq R, Iacobuzio-Donahue CA. Claudin 4 protein expression in primary and metastatic pancreatic cancer: support for use as a therapeutic target. Am J Clin Pathol 2004;121:226-30.
15. Montgomery E, Mamelak AJ, Gibson M, et al. Overexpression of claudin proteins in esophageal adenocarcinoma and its precursor lesions. Appl Immunohistochem Mol Morphol. In press 2006.
16. Michl P, Buchholz M, Rolke M, et al. Claudin-4: a new target for pancreatic cancer treatment using Clostridium perfringens enterotoxin. Gastroenterology 2001;121:678-84.
17. Kominsky SL, Vali M, Korz D, et al. Clostridium perfringens enterotoxin elicits rapid and specific cytolysis of breast carcinoma cells mediated through tight junction proteins claudin 3 and 4. Am J Pathol 2004;164:1627-33.
18. Manley S, Mucci NR, De Marzo AM, Rubin MA. Relational database structure to manage high-density tissue microarray data and images for pathology studies focusing on clinical outcome: the prostate specialized program of research excellence model. Am J Pathol 2001;159:837-43.
19. Xin W, Yun KJ, Ricci F, et al. MAP2K4/MKK4 expression in pancreatic cancer: genetic validation of immunohistochemistry and relationship to disease course. Clin Cancer Res 2004;10:8516-20.
20. Rahner C, Mitic LL, Anderson JM. Heterogeneity in expression and subcellular localization of claudins 2, 3, 4, and 5 in the rat liver, pancreas, and gut. Gastroenterology 2001;120:411-22.
21. Mhawech P, Greloz V, Assaly M, Herrmann F. Immunohistochemical expression of 14-3-3σ protein in human urological and gynecological tumors using a multi-tumor microarray analysis. Pathol Int 2005;55:77-82.
22. Cunningham SC, Kamangar F, Kim MP, et al. Survival after gastric adenocarcinoma resection: eighteen-year experience at a single institution. J Gastrointest Surg 2005;9:718-25.
23. Cunningham SC, Kamangar F, Kim MP, et al. Mkk4 status predicts survival after resection of gastric adenocarcinoma. Arch Surg. In press 2006.
24. Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic alterations during colorectal-tumor development. N Engl J Med 1988;319:525-32.
25. Maitra A, Adsay NV, Argani P, et al. Multicomponent analysis of the pancreatic adenocarcinoma progression model using a pancreatic intraepithelial neoplasia tissue microarray. Mod Pathol 2003;16:902-12.
26. Jass JR. Role of intestinal metaplasia in the histogenesis of gastric carcinoma. J Clin Pathol 1980;33:801-10.
27. Filipe MI, Potet F, Bogomoletz WV, et al. Incomplete sulphomucin- secreting intestinal metaplasia for gastric cancer. Preliminary data from a prospective study from three centres. Gut 1985;26:1319-26.
28. Filipe MI, Munoz N, Matko I, et al. Intestinal metaplasia types and the risk of gastric cancer: a cohort study in Slovenia. Int J Cancer 1994;57:324-9.
29. Huang CB, Xu J, Huang JF, Meng XY. Sulphomucin colonic type intestinal metaplasia and carcinoma in the stomach. A histochemical study of 115 cases obtained by biopsy. Cancer 1986;57:1370-5.
30. Rokkas T, Filipe MI, Sladen GE. Detection of an increased incidence of early gastric cancer in patients with intestinal metaplasia type III who are closely followed up. Gut 1991;32:1110-3.
31. El-Zimaity HM, Ramchatesingh J, Saeed MA, Graham DY. Gastric intestinal metaplasia: subtypes and natural history. J Clin Pathol 2001;54:679-83.
32. Ruol A, Parenti A, Zaninotto G, et al. Intestinal metaplasia is the probable common precursor of adenocarcinoma in Barrett esophagus and adenocarcinoma of the gastric cardia. Cancer 2000;88:2520-8.
33. Stemmermann GN, Fenoglio-Preiser C. Gastric carcinoma distal to the cardia: a review of the epidemiological pathology of the precursors to a preventable cancer. Pathology 2002;34:494-503.
34. Iacobuzio-Donahue CA, Maitra A, Olsen M, et al. Exploration of global gene expression patterns in pancreatic adenocarcinoma using cDNA microarrays. Am J Pathol 2003;162:1151-62.
35. Teng DH, Perry WL III, Hogan JK, et al. Human mitogen-activated protein kinase kinase 4 as a candidate tumor suppressor. Cancer Res 1997;57:4177-82.
36. Su GH, Hilgers W, Shekher MC, et al. Alterations in pancreatic, biliary, and breast carcinomas support MKK4 as a genetically targeted tumor suppressor gene. Cancer Res 1998;58:2339-42.
37. Parsons DW, Wang TL, Samuels Y, et al. Colorectal cancer: mutations in a signalling pathway. Nature 2005;436:792.
38. Xia Z, Dickens M, Raingeaud J, Davis RJ, Greenberg ME. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 1995;270:1326-31.
39. Wang L, Pan Y, Dai JL. Evidence of MKK4 pro-oncogenic activity in breast and pancreatic tumors. Oncogene 2004;23:5978-85.
40. Fu H, Subramanian RR, Masters SC. 14-3-3 Proteins: structure, function, and regulation. Annu Rev Pharmacol Toxicol 2000;40:617-47.
41. Hermeking H. The 14-3-3 cancer connection. Nat Rev Cancer 2003;3:931-43.
42. van Hemert MJ, Steensma HY, van Heusden GP. 14-3-3 proteins: key regulators of cell division, signalling and apoptosis. Bioessays 2001;23:936-46.
43. Iacobuzio-Donahue CA, Ashfaq R, Maitra A, et al. Highly expressed genes in pancreatic ductal adenocarcinomas: a comprehensive characterization and comparison of the transcription profiles obtained from three major technologies. Cancer Res 2003;63:8614-22.
44. Guweidhi A, Kleeff J, Giese N, et al. Enhanced expression of 14-3-3σ in pancreatic cancer and its role in cell cycle regulation and apoptosis. Carcinogenesis 2004;25:1575-85.
45. Nakanishi K, Hashizume S, Kato M, Honjoh T, Setoguchi Y, Yasumoto K. Elevated expression levels of the 14-3-3 family of proteins in lung cancer tissues. Hum Antibodies 1997;8:189-94.
46. Villaret DB, Wang T, Dillon D, et al. Identification of genes overexpressed in head and neck squamous cell carcinoma using a combination of complementary DNA subtraction and microarray analysis. Laryngoscope 2000;110:374-81.
47. Ferguson AT, Evron E, Umbricht CB, et al. High frequency of hypermethylation at the 14-3-3σ locus leads to gene silencing in breast cancer. Proc Natl Acad Sci U S A 2000;97:6049-54.
48. Cheng L, Pan CX, Zhang JT, et al. Loss of 14-3-3σ in prostate cancer and its precursors. Clin Cancer Res 2004;10:3064-8.
49. Iwata N, Yamamoto H, Sasaki S, et al. Frequent hypermethylation of CpG islands and loss of expression of the 14-3-3σ gene in human hepatocellular carcinoma. Oncogene 2000;19:5298-302.
50. Gasco M, Bell AK, Heath V, et al. Epigenetic inactivation of 14-3-3 óin oral carcinoma: association with p16(INK4a) silencing and human papillomavirus negativity. Cancer Res 2002;62:2072-6.
51. Gasco M, Sullivan A, Repellin C, et al. Coincident inactivation of 14-3-3σ and pl6INK4a is an early event in vulval squamous neoplasia. Oncogene 2002;21:1876-81.
52. Mirza ZK, Das KK, Slate J, et al. Gastric intestinal metaplasia as detected by a monoclonal antibody is highly associated with gastric adenocarcinoma. Gut 2003;52:807-12.
53. Grotzinger C, Kneifel J, Patschan D, et al. LI-cadherin: a marker of gastric metaplasia and neoplasia. Gut 2001;49:73-81.
54. Olliver JR, Wild CP, Sahay P, Dexter S, Hardie LJ. Chromoendoscopy with methylene blue and associated DNA damage in Barrett's oesophagus. Lancet 2003;362:373-4.